Anticancer therapy
Researchers at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center show for the first time that a molecule called EGR4 -known mainly for its role in male fertility — serves as a critical brake on immune activation. The study, published by EMBO Reports, shows that taking EGR4 away — effectively releasing the brake — promotes the activation of so-called killer T cells, which infiltrate and attack tumors and thereby boost anticancer immunity.
